ArticleSeminars in arthritis and rheumatism2015
Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.
Article in Seminars in arthritis and rheumatism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 77 citations in OpenAlex.
- Unique and shared transcriptomic signatures underlying localized scleroderma pathogenesis identified using interpretable machine learning.JCI insight · 2025Article
- Autoimmune pulmonary alveolar proteinosis developed during treatment for systemic sclerosis: a case report.BMC pulmonary medicine · 2025Article
- The role of selected cytokines from the interleukin 1 family in the pathophysiology of morphea.Archives of dermatological research · 2025Article
- Successful treatment of localized scleroderma using brodalumab: A case report.SAGE open medical case reports · 2025Article
- What Is New in Morphea-Narrative Review on Molecular Aspects and New Targeted Therapies.Journal of clinical medicine · 2024Review
- Interferon-Gamma-Inducible Protein-10 (IP-10) and Tumor Necrosis Factor-α (TNF-α) as Serological Predictors of Active Disease Status in Localized Scleroderma.International journal of molecular sciences · 2024Article
- Biomarkers in skin autoimmunity-An update on localised scleroderma.Skin health and disease · 2024Review
- Development of Morphea Following Treatment with an ADA Biosimilar: A Case Report.Current rheumatology reviews · 2024Article
- VariantThe New England journal of medicine · 2023Article
- Successful Treatment of Paediatric Morphea with Tofacitinib.Acta dermato-venereologica · 2023Article
- Morphea: The 2023 update.Frontiers in medicine · 2023Review
- Serum Levels of Selected IL-1 Family Cytokines in Patients with Morphea.Journal of clinical medicine · 2022Article
- GAAGs, COMP, and YKL-40 as Potential Markers of Cartilage Turnover in Blood of Children with Juvenile Idiopathic Arthritis Treated with Etanercept-Relationship with ADAMTS4, ADAMTS5, and PDGF-BB.Journal of clinical medicine · 2022Article
- Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma.Rheumatology (Oxford, England) · 2021Article
- Morphea: progress to date and the road ahead.Annals of translational medicine · 2021Review
- Genetic Signatures From RNA Sequencing of Pediatric Localized Scleroderma Skin.Frontiers in pediatrics · 2021Article
- IFN-γJournal of cellular and molecular medicine · 2020Article
- Association of juvenile idiopathic arthritis and morphea: a case series.Clinical rheumatology · 2020Review
- A novel patient-reported outcome for paediatric localized scleroderma: a qualitative assessment of content validity.The British journal of dermatology · 2020Article
- Overview of Juvenile localized scleroderma and its management.World journal of pediatrics : WJP · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo evaluate peripheral blood T-helper (TH) cell-associated cytokine and chemokine profiles in localized scleroderma (LS), and correlate them with clinical disease features, including disease activity parameters.
methodsA 29-plex Luminex platform was used to analyze the humoral profile of plasma samples from 69 pediatric LS patients and 71 healthy pediatric controls. Cytokine/chemokine levels were compared between these two groups and within LS patients, focusing on validated clinical outcome measures of disease activity and damage in LS.
resultsPlasma levels of IP-10, MCP-1, IL-17a, IL-12p70, GM-CSF, PDGF-bb, IFN-α2, and IFN-γ were significantly higher in LS subjects compared to healthy controls. Analysis within the LS group demonstrated IP-10, TNF-α, and GM-CSF correlated with clinical measures of disease activity. Several cytokines/chemokines correlated with anti-histone antibody, while only a few correlated with positive ANA and single-stranded DNA antibody.
conclusionThis is the first time that multiple cytokines and chemokines have been examined simultaneously in LS. In general, a TH1 (IFN-γ) and TH17 (IL-17a) predominance was demonstrated in LS compared to healthy controls. There is also an IFN-γ signature with elevated IP-10, MCP-1, and IFN-γ, which has been previously demonstrated in systemic sclerosis, suggesting a shared pathophysiology. Within the LS patients, those with active disease demonstrated IP-10, TNF-α, and GM-CSF, which may potentially serve as biomarkers of disease activity in the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.